• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Advisory Committee to Develop Master Protocols for COVID-19 Vaccines

FDA Advisory Committee to Develop Master Protocols for COVID-19 Vaccines

October 26, 2020

The FDA last week said it is developing master protocols for safety and effectiveness outcomes it intends to study for coronavirus vaccines. It will post the draft versions of those protocols for public comment and will eventually publish the final versions and final study reports online. The agency plans to identify and monitor 10 to 20 safety outcomes of interest, which will be done alongside the CDC and other government partners.

The announcement was made at a meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee, where the agency’s considerations for continuing blinded phase 3 trials after an Emergency Use Authorization (EUA) is issued were discussed.

Members of the expert panel expressed concerns about making sure minority and pediatric populations will be adequately represented in COVID-19 vaccine trials. Cody Meissner, chief of Pediatric Infectious Diseases at Tufts Children’s Hospital, called for pediatric patients to be evaluated as a distinct group because the disease impacts them differently.

Most members of the committee believe that the continuation of blinded phase 3 trials is essential, while some said there are ethical considerations.

Luigi Notarangelo, head of the National Institute of Allergy and Infectious Diseases’ laboratory of clinical immunology and microbiology, said that the “continuation of blinded phase 3 trials is absolutely critical, and we should do all that we can to make sure that they continue.”

Acting Committee Chairman Arnold Monto, an epidemiology professor at the University of Michigan, echoed the same sentiments, arguing that “unblinding destroys the whole purpose of a randomized trial.” He did, however, acknowledge the ethical dilemma of granting an EUA while continuing to give trial participants placebos.

The FDA may also conduct its own studies, including ones for general effectiveness and duration of protection. The FDA, the Centers for Medicare and Medicaid Services and the CDC have extensive experience in assessing the effectiveness of vaccines, Anderson said, having created several effectiveness studies for influenza and shingles vaccines.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing